Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

75.91EUR
21 Nov 2014
Price Change (% chg)

€0.89 (+1.19%)
Prev Close
€75.02
Open
€74.71
Day's High
€76.33
Day's Low
€73.86
Volume
6,031,555
Avg. Vol
3,856,300
52-wk High
€89.95
52-wk Low
€68.29

SASY.PA

Chart for SASY.PA

About

Sanofi, formerly Sanofi-Aventis is a global and diversified healthcare company. The Company discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi focuses on the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer... (more)

Overall

Beta: 0.61
Market Cap (Mil.): €99,549.70
Shares Outstanding (Mil.): 1,326.97
Dividend: 2.80
Yield (%): 3.73

Financials

  SASY.PA Industry Sector
P/E (TTM): 24.31 38.05 39.20
EPS (TTM): 3.09 -- --
ROI: -- 17.86 17.16
ROE: -- 18.61 18.09
Search Stocks

BRIEF-Zealand Pharma informs that Sanofi has confirmed development plans for LixiLan

* Zealand informs that Sanofi has confirmed development plans for LixiLan at Investor Relations Thematic Seminar

21 Nov 2014

Sanofi touts new drugs but diabetes outlook disappoints

PARIS - Sanofi , which sacked its chief executive three weeks ago, gave a weak sales outlook for its diabetes drugs on Thursday, overshadowing plans to reap more than 30 billion euros (23.97 billion pounds) from new medicines.

20 Nov 2014

UPDATE 4-Sanofi touts new drugs but diabetes outlook disappoints

* Sees up to six new drug launches in 2015, 18 by end 2020

20 Nov 2014

BRIEF-Sanofi chairman comments on drugmaker's outlook

PARIS, Nov 20 - Sanofi Chairman Serge Weinberg to reporters on a conference call on Thursday:

20 Nov 2014

Sanofi touts new drugs but diabetes outlook disappoints

PARIS - Sanofi, which sacked its chief executive three weeks ago, gave a weak sales outlook for its diabetes drugs on Thursday, overshadowing plans to reap more than 30 billion euros ($38 billion) from new medicines.

20 Nov 2014

Sanofi, Regeneron eczema drug gets FDA fast-track designation

PARIS, Nov 20 - Sanofi and its U.S. partner Regeneron said on Thursday the U.S. Food and Drug Administration had designated their dupilumab drug as "breakthrough therapy" in the treatment of atopic dermatitis, a chronic form of eczema, granting the product a fast-track development and review process.

20 Nov 2014

Without CEO, Sanofi touts new drugs in its pipeline

PARIS - Sanofi set out its strategy for bringing several new drugs to the market on Thursday, in a bid to win over investors alarmed by the sudden ouster of its chief executive and problems in the field of diabetes.

20 Nov 2014

Without CEO, Sanofi touts new drugs in its pipeline

PARIS, Nov 20 - Sanofi set out its strategy for bringing several new drugs to the market on Thursday, in a bid to win over investors alarmed by the sudden ouster of its chief executive and problems in the field of diabetes.

20 Nov 2014

Sanofi draws up candidate shortlist for top job - source

PARIS - Sanofi is drawing up a shortlist of candidates for the post of chief executive to replace Chris Viehbacher, ousted by the board last month, a source close to the French drugmaker told Reuters.

18 Nov 2014

UPDATE 1-Sanofi draws up candidate shortlist for top job -source

* Fourtou to lead appointments and governance committee -source

18 Nov 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Reuters Investment Profile
£10.00
Provider: Thomson Reuters ONE
£0.00
Provider: Thomson Reuters ONE
£0.00
Provider: Thomson Reuters ONE
£0.00
Provider: Thomson Reuters ONE
£0.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks